- Home
- XENE vs VCEL Comparison
XENE vs VCEL Comparison
Compare XENE & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XENE
- VCEL
- Stock Information
- Founded
- XENE 1996
- VCEL 1989
- Country
- XENE Canada
- VCEL United States
- Employees
- XENE N/A
- VCEL N/A
- Industry
- XENE Biotechnology: Pharmaceutical Preparations
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XENE Health Care
- VCEL Health Care
- Exchange
- XENE Nasdaq
- VCEL Nasdaq
- Market Cap
- XENE 2.4B
- VCEL 2.1B
- IPO Year
- XENE 2014
- VCEL 1997
- Fundamental
- Price
- XENE $32.63
- VCEL $39.98
- Analyst Decision
- XENE Strong Buy
- VCEL Strong Buy
- Analyst Count
- XENE 11
- VCEL 8
- Target Price
- XENE $54.82
- VCEL $62.00
- AVG Volume (30 Days)
- XENE 1.5M
- VCEL 463.0K
- Earning Date
- XENE 08-07-2025
- VCEL 07-31-2025
- Dividend Yield
- XENE N/A
- VCEL N/A
- EPS Growth
- XENE N/A
- VCEL 521.85
- EPS
- XENE N/A
- VCEL 0.05
- Revenue
- XENE $7,500,000.00
- VCEL $238,541,000.00
- Revenue This Year
- XENE N/A
- VCEL $23.03
- Revenue Next Year
- XENE $253.71
- VCEL $24.52
- P/E Ratio
- XENE N/A
- VCEL $771.35
- Revenue Growth
- XENE N/A
- VCEL 14.80
- 52 Week Low
- XENE $26.74
- VCEL $37.39
- 52 Week High
- XENE $46.00
- VCEL $63.00
- Technical
- Relative Strength Index (RSI)
- XENE 51.18
- VCEL 42.08
- Support Level
- XENE $31.22
- VCEL $39.39
- Resistance Level
- XENE $33.51
- VCEL $42.61
- Average True Range (ATR)
- XENE 1.18
- VCEL 1.61
- MACD
- XENE 0.04
- VCEL -0.20
- Stochastic Oscillator
- XENE 45.62
- VCEL 11.60
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.